Hepatitis B & C

Each year, nearly 1 million people worldwide die due to hepatitis B or hepatitis C, forms of viral hepatitis that cause liver inflammation and over time can lead to cirrhosis or liver cancer. Hepatitis B is endemic in China and eastern Asia, where most people become infected during childhood, and many of the 150 million people who are chronically infected with hepatitis C live in the Asia Pacific region.

Since 2002, the Bristol-Myers Squibb Foundation’s Delivering Hope™ initiative has been helping communities and healthcare workers in China and India effectively raise awareness about the dangers of hepatitis B and hepatitis C, inform health policy and national programs, build the capacity of healthcare providers and communities to address these diseases, and promote disease prevention in the hardest-hit and greatest at-risk populations.

Delivering Hope has awarded more than $15 million to 50 projects in Asia since 2002. In China alone, more than 8 million people who are at high risk of hepatitis infection have benefitted from Delivering Hope programs over the past decade.

The World Health Organization estimates that between 130 million and 150 million people worldwide are infected with the hepatitis C virus (HCV). While sub-Saharan Africa is among the hardest hit areas, a lack of information about who and how HCV is affecting the region is hampering an effective response. The Bristol-Myers Squibb Foundation’s SECURE THE FUTURE® initiative is expanding on its work in HIV, tuberculosis and cervical and breast cancers in sub-Saharan Africa to determine the scope of HCV infection in the region, help establish screening and treatment guidelines for Africa and use established models that increase access to care for key populations.


Hepatitis B & C in China and India

Triangle Icon

Hepatitis C in sub-Saharan Africa

Triangle Icon